Bristol Myers Squibb joined Hengrui in a broad alliance that covers 13 drug programs, with deal value up to $15.2 billion. The pact reflects the deepening relationship between China-based large pharma and Western developers seeking pipeline scale and development throughput. Under the arrangement, BMS pays $600 million upfront and advances early-stage programs drawn across both companies’ pipelines. The total value can rise with development, regulatory, and commercial milestones. For Hengrui, the deal adds another major U.S./European partner to its portfolio of collaborations, while for BMS it strengthens access to multiple candidates spanning mechanisms intended for oncology and other therapeutic areas.